ReviewMolecular diversity2026
Advancement in peptide-based therapeutics for the treatment of type 2 diabetes mellitus: current progress and future prospects.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a chronic medical disorder caused by insufficient production of the hormone insulin by the pancreas. Although there are various treatment options available for controlling diabetes, including non-peptide-based medications, the majority of these have adverse effects and are limited in comparison to peptide-based drugs. Protein drugs offer numerous benefits, including weight loss, significant reductions in blood glucose levels, and an extremely low risk of hypoglycemia. This article discusses treatment modalities, presents existing therapies, provides an in-depth comparison of peptide-based and other drugs, examines current development and barriers, offers some recommendations, and outlines future research directions for peptide drugs in the treatment of T2DM. In recent days, several computational tools and AI models, including ESMFold, ProteinMPNN, Schrödinger, and AutoDock Vina, have played an essential role in peptide-based drug discovery. Therefore, this article also highlights the significance of AI drug discovery, diverse AI models, and other computational tools to enhance peptide-based drug discovery and development.
Indexed as
Identifiers
41746526What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.